Otol Neurotol:银屑病与听力损失和前庭功能障碍有关

2022-09-05 sunshine MedSci原创

银屑病皮损常出现在耳廓和外耳道,但中耳和内耳的表现不容易被识别。一些研究表明,听力损失和前庭功能障碍与银屑病有关,但相关程度尚不清楚。

银屑病皮损常出现在耳廓和外耳道,但中耳和内耳的表现不容易被识别。一些研究表明,听力损失和前庭功能障碍与银屑病有关,但相关程度尚不清楚。近日,发表于Otol Neurotol的一项系统回顾和荟萃分析对此进行了探究。

研究人员系统检索了PubMed、CINAHL、Scopus和Cochrane图书馆数据库,纳入的研究描述了银屑病患者的听力或前庭评估。Meta分析用几率(ORs)或平均差异(MD)表示,并设置了95%的置信区间。

 

结果,共纳入13项研究,涉及589名银屑病患者和617名健康对照者。银屑病患者(47.1 [12.4] 岁)和健康对照组(45.4 [11.2] 岁)之间的年龄没有明显差异。银屑病面积和严重程度指数评分为9.9(8.4),体表面积评分为7.9(14.7)。纯音测听分析结果显示,与健康对照组相比,银屑病患者所有频率的平均听力阈值较高,其中4000赫兹的差异最大(MD,7.70 [4.46-10.94];P < 0.00001)。银屑病患者的语言接收阈值更差(MD,3.53 [1.56-5.49];P < 0.0001)。银屑病患者镫骨反射异常更常见(OR,5.19 [1.68-15.99];P = 0.004)。银屑病患者的前庭测试异常在冷热试验中更常见(OR,13.12 [2.88-59.84];P < 0.0001)。对41,681名银屑病患者和80,273名健康对照组进行的另外两项研究发现,银屑病患者发生突发性感音神经性听力损失的风险更高(OR,1.50 [1.25-1.80];P < 0.0001)。

综上所述,该研究结果表明,银屑病与听力损失和前庭功能障碍有关,但临床意义仍未确定。该研究所发现的趋势需要更多的调查,病理生理学机制也需要进一步探究。

 

原始出处:

 

Seth S Jeong, et al., Otologic Manifestations of Psoriasis: A Systematic Review and Meta-Analysis. Otol Neurotol. 2022 Aug 1;43(7):742-752. doi: 10.1097/MAO.0000000000003597.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2080498, encodeId=f1b52080498a1, content=<a href='/topic/show?id=db063259162' target=_blank style='color:#2F92EE;'>#前庭功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32591, encryptionId=db063259162, topicName=前庭功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sun Nov 20 11:02:00 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306735, encodeId=38db1306e35a6, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Sep 04 15:02:00 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421465, encodeId=70561421465c6, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sun Sep 04 15:02:00 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538334, encodeId=74b715383342b, content=<a href='/topic/show?id=e1983258976' target=_blank style='color:#2F92EE;'>#前庭功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32589, encryptionId=e1983258976, topicName=前庭功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddff12959974, createdName=sjq031, createdTime=Sun Sep 04 15:02:00 CST 2022, time=2022-09-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2080498, encodeId=f1b52080498a1, content=<a href='/topic/show?id=db063259162' target=_blank style='color:#2F92EE;'>#前庭功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32591, encryptionId=db063259162, topicName=前庭功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sun Nov 20 11:02:00 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306735, encodeId=38db1306e35a6, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Sep 04 15:02:00 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421465, encodeId=70561421465c6, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sun Sep 04 15:02:00 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538334, encodeId=74b715383342b, content=<a href='/topic/show?id=e1983258976' target=_blank style='color:#2F92EE;'>#前庭功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32589, encryptionId=e1983258976, topicName=前庭功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddff12959974, createdName=sjq031, createdTime=Sun Sep 04 15:02:00 CST 2022, time=2022-09-04, status=1, ipAttribution=)]
    2022-09-04 ysjykql
  3. [GetPortalCommentsPageByObjectIdResponse(id=2080498, encodeId=f1b52080498a1, content=<a href='/topic/show?id=db063259162' target=_blank style='color:#2F92EE;'>#前庭功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32591, encryptionId=db063259162, topicName=前庭功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sun Nov 20 11:02:00 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306735, encodeId=38db1306e35a6, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Sep 04 15:02:00 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421465, encodeId=70561421465c6, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sun Sep 04 15:02:00 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538334, encodeId=74b715383342b, content=<a href='/topic/show?id=e1983258976' target=_blank style='color:#2F92EE;'>#前庭功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32589, encryptionId=e1983258976, topicName=前庭功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddff12959974, createdName=sjq031, createdTime=Sun Sep 04 15:02:00 CST 2022, time=2022-09-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2080498, encodeId=f1b52080498a1, content=<a href='/topic/show?id=db063259162' target=_blank style='color:#2F92EE;'>#前庭功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32591, encryptionId=db063259162, topicName=前庭功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sun Nov 20 11:02:00 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306735, encodeId=38db1306e35a6, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Sep 04 15:02:00 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421465, encodeId=70561421465c6, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sun Sep 04 15:02:00 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538334, encodeId=74b715383342b, content=<a href='/topic/show?id=e1983258976' target=_blank style='color:#2F92EE;'>#前庭功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32589, encryptionId=e1983258976, topicName=前庭功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddff12959974, createdName=sjq031, createdTime=Sun Sep 04 15:02:00 CST 2022, time=2022-09-04, status=1, ipAttribution=)]

相关资讯

J Invest Dermatol:阿达木单抗联合低剂量甲氨蝶呤能更好的治疗银屑病

阿达木单抗是一种 TNF-α抑制剂,常被用于治疗银屑病患者。然而,免疫原性(即抗药性抗体[ADA]的形成)是导致阿达木单抗治疗失败的一个重要因素。

Dermatol Ther:与口服甲氨蝶呤相比,皮下注射甲氨蝶呤治疗银屑病的效果似乎更加

与口服MTX相比,皮下注射甲氨蝶呤被认为与更高和可预测的线性生物利用度有关。尽管各种研究报告显示,SC MTX对银屑病是安全和有效的,但关于口服和SC MTX的前瞻性头对头比较试验是有限。

Probiotics Antimicrob Proteins:口服唾液链球菌K-12改善银屑病

银屑病是一种常见的慢性皮肤病,本文首次将唾液链球菌K-12用于控制银屑病治疗,对198例轻、中度银屑病患者进行了回顾性分析以确定其对银屑病的作用。

J Immunol Res:Risankizumab与Ustekinumab治疗银屑病疗效和安全性比较

银屑病是一种常见的慢性炎症性皮肤病,本研究的目的是严格评价ustekinumab和risankizumab治疗银屑病的疗效和安全性,为临床决策提供参考。

Front Med:降脂药物可以治疗银屑病吗?

据报道银屑病与脂代谢密切相关,银屑病患者最近有血脂水平异常,本文通过回顾相关文献,包括涉及降脂药物的临床和临床前研究,旨在确定降脂药物治疗银屑病的安全性和有效性,并阐明其作用机制。

Exp Dermatol:死海气候疗法治疗银屑病在短期内是一种有效的抗炎疗法

气候疗法是一种治疗银屑病的著名疗法。以色列的死海气候疗法(DSC在改善临床和患者报告的结果方面非常有效,本研究旨在通过定量免疫组织化学技术和血样分析来研究DSC对银屑病皮肤的影响。